- The article explains that healthcare companies involved in treating obesity are concerned that the introduction of powerful weight-loss drugs, such as Novo Nordisk's Wegovy, may negatively impact their businesses, leading to a sell-off in related companies. The high prices of the weight-loss drugs, uncertainty about long-term usage, and potential lack of insurance coverage are seen as potential limitations for the market. As a result, stocks of companies involved in bariatric surgery devices and products addressing health issues related to excess weight, such as diabetes and sleep apnea, have seen declines. Intuitive Surgical's stock, in particular, went down by 0.2% last night due to these concerns.
- Intuitive Surgical (ISRG) stock went down last night by 0.75% following the company's announcement of its financial results for the third quarter of 2023, which showed an increase in revenue, but a decrease in systems revenue compared to the same period in 2022.
- The article discusses the growth and potential of the global robot market, which is expected to reach $231.48 billion by 2030 with a CAGR of 15.3% from 2022 to 2030. It mentions key players in the market and highlights the increasing adoption of robots in industries such as e-commerce. However, there is no explanation given for the decline in Intuitive Surgical (ISRG) stock.
- Intuitive Surgical's stock went down due to the growing popularity of weight-loss drugs, such as Novo Nordisk's Wegovy and Eli Lilly's Mounjaro, which are affecting the demand for weight-loss surgeries and procedures that use surgical robots.
- Intuitive Surgical (ISRG) stock went down by 0.75% because the company missed analysts' estimates for quarterly sales, mainly due to easing demand for its robots used in bariatric surgeries as more patients opt for weight-loss drugs.
- Intuitive Surgical (ISRG) stock went down because the popularity of weight-loss drugs, such as Novo Nordisk's Wegovy and Eli Lilly's Mounjaro, is reducing demand for bariatric surgeries, which affects the demand for surgical robots made by Intuitive Surgical.
- The article discusses why DexCom stock may be a better healthcare pick compared to Intuitive Surgical stock, citing Intuitive Surgical's superior profitability and financial position as the reason for its recent increase in stock value.
- Shares of Intuitive Surgical Inc. (ISRG) increased by 0.34% as the overall stock market performed well, with the S&P 500 and Dow Jones Industrial Average also rising. The stock outperformed some of its competitors such as Medtronic and Stryker.
- Intuitive Surgical (ISRG) stock went up by 0.34% due to a positive trading session for the stock market as a whole, with the S&P 500 and Dow Jones Industrial Average also rising.
- The article discusses two stocks that are part of billionaire stock picker Ken Fisher's portfolio, Charles Schwab (SCHW) and Intuitive Surgical (ISRG). Fisher believes in the importance of patience in navigating the stock market, and he sees potential in both of these stocks. The article provides an overview of each company and highlights the positive outlook from analysts. In the case of Charles Schwab, the analyst consensus rates it as a Strong Buy, and the future looks bright for the financial giant due to factors such as NIM expansion and the realization of integration synergies. Regarding Intuitive Surgical, the company is a pioneer in minimally invasive surgery and experienced strong growth in procedures and revenue. Analysts see sizeable opportunities, particularly in China, which could contribute to significant revenue growth. Both stocks have the potential for significant upside in the coming year.
- The article discusses the comparison between healthcare stocks Intuitive Surgical (ISRG) and DexCom (DXCM), concluding that although ISRG stock has performed better this year, DXCM stock is expected to offer better returns in the next three years due to factors such as revenue growth and profitability. The reason for the recent increase in ISRG stock is not mentioned in the article.